The Protective Effect of the Mycobacterium bovis BCG Vaccine Is Increased by Coadministration with the Mycobacterium tuberculosis 72-Kilodalton Fusion Polyprotein Mtb72F in M. tuberculosis -Infected Guinea Pigs
- 1 November 2004
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 72 (11) , 6622-6632
- https://doi.org/10.1128/iai.72.11.6622-6632.2004
Abstract
A tuberculosis vaccine candidate consisting of a 72-kDa polyprotein or fusion protein based upon the Mtb32 and Mtb39 antigens of Mycobacterium tuberculosis and designated Mtb72F was tested for its protective capacity as a potential adjunct to the Mycobacterium bovis BCG vaccine in the mouse and guinea pig models of this disease. Formulation of recombinant Mtb72F (rMtb72F) in an AS02A adjuvant enhanced the Th1 response to BCG in mice but did not further reduce the bacterial load in the lungs after aerosol challenge infection. In the more stringent guinea pig disease model, rMtb72F delivered by coadministration with BCG vaccination significantly improved the survival of these animals compared to BCG alone, with some animals still alive and healthy in their appearance at >100 weeks post-aerosol challenge. A similar trend was observed with guinea pigs in which BCG vaccination was boosted by DNA vaccination, although this increase was not statistically significant due to excellent protection conferred by BCG alone. Histological examination of the lungs of test animals indicated that while BCG controls eventually died from overwhelming lung consolidation, the majority of guinea pigs receiving BCG mixed with rMtb72F or boosted twice with Mtb72F DNA had mostly clear lungs with minimal granulomatous lesions. Lesions were still prominent in guinea pigs receiving BCG and the Mtb72F DNA boost, but there was considerable evidence of lesion healing and airway remodeling and reestablishment. These data support the hypothesis that the coadministration or boosting of BCG vaccination with Mtb72F may limit the lung consolidation seen with BCG alone and may promote lesion resolution and healing. Collectively, these data suggest that enhancing BCG is a valid vaccination strategy for tuberculosis that is worthy of clinical evaluation.Keywords
This publication has 27 references indexed in Scilit:
- Improving vaccines against tuberculosisImmunology & Cell Biology, 2003
- Immunopathogenesis of Pulmonary Granulomas in the Guinea Pig after Infection withMycobacterium tuberculosisInfection and Immunity, 2003
- Enhanced Immunogenicity to Mycobacterium tuberculosis by Vaccination with an Alphavirus Plasmid Replicon Expressing Antigen 85AInfection and Immunity, 2003
- Evolution of WHO policies for tuberculosis control, 1948–2001The Lancet, 2002
- Priming by DNA Immunization Augments Protective Efficacy ofMycobacterium bovisBacille Calmette-Guerin against TuberculosisInfection and Immunity, 2001
- Boosting Vaccine for TuberculosisInfection and Immunity, 2001
- NEW VACCINES AGAINST TUBERCULOSIS: The Status of Current ResearchInfectious Disease Clinics of North America, 1999
- A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalariaNew England Journal of Medicine, 1997
- Tuberculosis: Commentary on a Reemergent KillerScience, 1992
- Tuberculosis in developing countries and methods for its controlTransactions of the Royal Society of Tropical Medicine and Hygiene, 1990